北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 作废部分限制性股票并调整限制性股票激励计划 归属价格的 法 律 意 见 书 北京市康达（广州）律师事务所 BEIJING KANGDA LAW FIRM Guangzhou Branch 地址：广州市珠江新城珠江东路 32 号利通广场 29 层 邮政编码：510630 电话：020-37392666 传真：020-37392826 1 北京市康达（广州）律师事务所 法律意见书 关于博济医药科技股份有限公司 作废部分限制性股票并调整限制性股票激励计划 归属价格的 法 律 意 见 书 致：博济医药科技股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受博济医药科技股份有 限公司（下称"博济医药"或"公司"）委托，根据《公司法》《证券法》等法律、 法规和规范性文件的有关规定，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神就博济医药 2023 年限制性股票激励计划、2024 年限制性股票激励计划 所涉及的相关事项出具法律意见。为出具本法律意见书，本所及本所律师声明如 下： 三、为出具本法律意见书，本所 ...

北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 调整股票期权激励计划行权价格的 法 律 意 见 书 北京市康达（广州）律师事务所 BEIJING KANGDA LAW FIRM Guangzhou Branch 地址：广州市珠江新城珠江东路 32 号利通广场 29 层 邮政编码：510630 电话：020-37392666 传真：020-37392826 1 北京市康达（广州）律师事务所 法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 调整股票期权激励计划行权价格的 法 律 意 见 书 致：博济医药科技股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受博济医药科技股份有 限公司（下称"博济医药"或"公司"）委托，根据《公司法》《证券法》等法律、 法规和规范性文件的有关规定，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，就博济医药 2022 年股票期权激励计划调整股票期权激励计划行权价 格的事项出具法律意见。为出具本法律意见书，本所及本所律师声明如下： 一、本所及本所律师依据《证券法》《公司法》《上市公司股权激励管 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-057 博济医药科技股份有限公司 表决结果：同意 3 票；反对 0 票；弃权 0 票。 2、 审议通过了《关于作废部分限制性股票并调整限制性股票激励计划归属 价格的议案》 经审核，监事会一致认为：公司本次作废部分限制性股票并调整限制性股票 激励计划归属价格事项符合公司《2023 年限制性股票激励计划（草案）》《2024 年限制性股票激励计划（草案）》等有关规定，不存在损害公司及全体股东利益 的情形。因此，公司监事会同意本次作废部分限制性股票并调整限制性股票激励 计划归属价格事项。 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届监事会第十四次会 议于 2025 年 7 月 15 日在公司会议室召开，会议采取现场投票方式对议案进行表 决。本次会议通知于 2025 年 7 月 11 日以专人送达、电子邮件、电话、微信等方 式发出。会议应到监事 3 人，实到 3 人。会议由监事会主席刘菁纯女士主 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-056 博济医药科技股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届董事会第十五次会 议于 2025 年 7 月 15 日在公司会议室召开，会议采取现场结合通讯投票的方式对 议案进行表决。本次会议通知于 2025 年 7 月 11 日以专人送达、电子邮件、电话、 微信等方式发出。会议应到董事 7 人，实到 7 人，会议由董事长王廷春先生主持， 部分监事和部分高管列席了本次董事会。本次董事会的召集、召开符合《公司法》 《公司章程》及相关法规的规定。 二、董事会会议审议情况 1、 审议通过了《关于调整股票期权激励计划行权价格的议案》 鉴于公司完成了 2024 年年度权益分派，根据公司《2022 年股票期权激励计 划（草案）》《2022 年股票期权激励计划实施考核管理办法》等有关规定，公司 董事会同意相应调整股票期权的行权价格。 本议案已经公司董事会薪酬与考核委员会审议通过。 表决结 ...

一、对外投资概述 证券代码：300404 证券简称：博济医药 公告编号：2025-054 博济医药科技股份有限公司 关于南阳中医药基金相关事项变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2022 年 1 月 26 日，博济医药科技股份有限公司（以下简称"公司"）召开 第四届董事会第十七次会议，审议通过了《关于全资子公司参与投资南阳中医药 基金的议案》，同意公司全资子西藏博济投资管理有限公司（以下简称"博济投 资"）作为有限合伙人参与投资南阳现代中医药私募投资基金（有限合伙）（以下 简称"合伙企业"），具体内容详见公司于 2022 年 1 月 27 日在巨潮资讯网 （http://www.cninfo.com.cn/）上披露的《关于全资子公司参与投资南阳中医药基 金的公告》（公告编号：2022-011）。合伙企业总规模为人民币 100,000 万元，博 济投资以自有资金出资 6,000 万元，占总出资额的 6.00%。合伙企业的合伙人及 出资情况如下： | 序号 | 合伙人 | 出资额 | 出资比 | 合伙人类别 | 出资 | | --- | - ...

特别提示： 1、本次归属限制性股票的激励对象合计 22 名，归属限制性股票数量合计 1, 140,000 股，占目前公司总股本的 0.2973%； 2、本次归属股份的上市流通日：2025 年 7 月 7 日。 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第五届董事会第十三次会议和第五届监事会第十二次会议，审议通过了《关于 公司 2024 年限制性股票激励计划第一个归属期归属条件成就的议案》，董事会 认为公司 2024 年限制性股票激励计划（以下简称"本激励计划"）第一个归属 期归属条件已成就。近日，公司办理了第一个归属期归属股份的登记工作。现将 有关情况公告如下： 一、公司 2024 年限制性股票激励计划概述及已履行的相关程序 1、 2024 年 3 月 19 日，公司第五届董事会第六次会议审议通过了《关于公 司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2024 年 限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会 办理 2024 年限制性股票激励计划相关事宜的议案》等议案。同日，公司第五届 监事会第六次会议审议通过 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

近日，博济医药科技股份有限公司（以下简称"公司"）全资子公司杏林中 医药科技（广州）有限公司获得国家知识产权局颁发的两项发明专利证书，具体 情况如下： 一、专利基本情况 证券代码：300404 证券简称：博济医药 公告编号：2025-052 博济医药科技股份有限公司 关于全资子公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 序号 | 发明名称 | 专利权人 | 证书号 | 专利号 | | 专利申请日 | | | 授权公告日 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种高生物利用 度的西红花酸钠 纳米复杂制剂、 | 杏林中医药 科技（广州） | 第8034214号 | | | | | | 年 06 日 27 | | | | | | ZL 2024 1 | 2024 | 年 | 01 | 2025 | | | | | | | 0078631.9 | 月 | 18 | 日 | 月 | | | | 制备方法、药物 | 有限公司 | | | ...

博济医药科技股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 博济医药科技股份有限公司（以下简称"公司"）近日接到公司控股股东王 廷春先生的通知，获悉王廷春先生将其所持有的公司部分股份在国泰海通证券股 份有限公司（以下简称"国泰海通"，原名"国泰君安证券股份有限公司"）办理 了股份质押展期的手续，具体事项如下： 证券代码：300404 证券简称：博济医药 公告编号：2025-051 注 1：王廷春先生、赵伶俐女士所持限售股份性质为高管锁定股，故上表中的"已质押股份限售和冻 结数量"及"未质押股份限售和冻结数量"均系高管锁定股。 一、股东股份质押展期的基本情况 | 股东名 | 是否为第一 | 本次质押 | 占其所 | 占公司 | 是否为 | 是否为 | 质押开始 | | 原质押 | | 展期后 | | 质权 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股 ...

Group 1 - The Chongqing Liangjiang New Area has gathered multiple pilot test platforms represented by companies like Boji Pharmaceutical, Boteng Pharmaceutical, and Huaguan Biotechnology, providing "one-stop" services for the acceleration of scientific research results into industrialization [1][3] - Pilot test platforms are comprehensive support platforms that facilitate the transition of research results from laboratory development to large-scale industrial production, playing a key role in the commercialization of innovative outcomes [3] - The Ministry of Industry and Information Technology and the National Development and Reform Commission aim to cultivate over 20 pilot test capability construction platforms by 2027, serving more than 200 companies and incubating over 400 products [3] Group 2 - Boji Pharmaceutical's subsidiary, Chongqing Boji Pharmaceutical Co., Ltd., focuses on high-tech barrier and high R&D cost complex injection drug development and production, with a platform that includes R&D laboratories, quality testing centers, and sterile injection production workshops [4] - The company has incubated 8 pharmaceutical enterprises to date and aims to assist more clients in completing multiple major complex injection drugs for the first time in China, as well as achieving international registration and market expansion [4] - Boteng Pharmaceutical, also located in the Water and Soil New City, provides one-stop service solutions for small molecule drugs, peptides, oligonucleotide drugs, protein and conjugate drugs, and cell and gene therapy drugs, covering the entire lifecycle from preclinical research to drug commercialization [4] Group 3 - The Liangjiang New Area is recognized as a core area for the development of the life and health industry, currently hosting 25 various platforms related to technical services, administrative regulation, industrial incubation, scientific innovation, and clinical services [5] - The area is continuously optimizing its industrial ecosystem and improving its service system to inject momentum into the collaborative innovation development of the biopharmaceutical industry chain [5]